Aerovate Therapeutics (NASDAQ:AVTE) Announces Quarterly Earnings Results

Aerovate Therapeutics (NASDAQ:AVTE) posted its earnings results on Tuesday. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.03, Zacks reports.

Aerovate Therapeutics Stock Performance

Shares of NASDAQ:AVTE opened at $2.56 on Friday. Aerovate Therapeutics has a 52-week low of $1.25 and a 52-week high of $32.42. The stock’s fifty day simple moving average is $2.20 and its 200-day simple moving average is $6.31.

About Aerovate Therapeutics

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.